A targeted extracorporeal therapy for endotoxemia: the time has come

doi:10.1186/cc5918

Critical Care
Volume 11
Issue 3

Viewing options:

Abstract
Full text
PDF (34KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Kellum JA

on PubMed

Kellum JA
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Commentary

A targeted extracorporeal therapy for endotoxemia: the time has come

John A Kellum

The CRISMA Laboratory, Critical Care Medicine, University of Pittsburgh, Terrace Street, Pittsburgh, PA 15261, USA

author email corresponding author email

Critical Care 2007, 11:137doi:10.1186/cc5918


Published:	8 June 2007

See related research by Cruz et al., http://ccforum.com/content/11/2/R47

Abstract

Endotoxemia, whether primary (due to Gram-negative infection) or secondary (due to epithelial barrier dysfunction), appears to be extremely common in the critically ill and injured. High levels of endotoxin activity are associated with worse clinical outcomes. In Japan, polymyxin B hemoperfusion has been available to treat endotoxemia for more than ten years. Multiple small trials, often limited by methodological quality, show that polymyxin B hemo-perfusion may have favorable effects on survival and hemodynamics. Further study of this therapy would seem justified.